Literature DB >> 5767016

Drug-induced changes of extracerebral dopa metabolism in man.

R Tissot, G Bartholini, A Pletscher.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1969        PMID： 5767016     DOI： 10.1001/archneur.1969.00480080087010

Source DB:  PubMed          Journal:  Arch Neurol        ISSN： 0003-9942


× No keyword cloud information.
  14 in total

1.  Influence of the decarboxylase inhibitor benserazide on the antihypertensive effect and metabolism of alpha-methyldopa in patients with essential hypertension.

Authors:  G Planz; H W Gierlichs; A Hawlina; R Planz; W Stephany; K H Rahn
Journal:  Eur J Clin Pharmacol       Date:  1977-12-02       Impact factor: 2.953

Review 2.  Levodopa: a review of its pharmacological properties and therapeutic use with particular reference to Parkinsonism.

Authors:  R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1971       Impact factor: 9.546

3.  Changes in taste under L-DOPA therapy.

Authors:  J Siegfried; H Zumstein
Journal:  Z Neurol       Date:  1971

4.  Intestinal decarboxylation of L-Dopa in relation to dose requirement in Parkinson's disease.

Authors:  A K Granerus; R Jagenburg; A Svanborg
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1973       Impact factor: 3.000

5.  Decarboxylation of orally administered L-dopa in the human digestive tract.

Authors:  J Bergmark; A Carlsson; A K Granerus; R Jagenburg; T Magnusson; A Svanborg
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1972       Impact factor: 3.000

6.  L-dopa level in plasma, primary condition for the kinetic effect.

Authors:  W Birkmayer; W Danielcyk; E Neumayer; P Riederer
Journal:  J Neural Transm       Date:  1973       Impact factor: 3.575

Review 7.  Clinical pharmacokinetics of anti-parkinsonian drugs.

Authors:  J M Cedarbaum
Journal:  Clin Pharmacokinet       Date:  1987-09       Impact factor: 6.447

Review 8.  Cystathionine-β-Synthase: Molecular Regulation and Pharmacological Inhibition.

Authors:  Karim Zuhra; Fiona Augsburger; Tomas Majtan; Csaba Szabo
Journal:  Biomolecules       Date:  2020-04-30

Review 9.  Clinical pharmacokinetics of levodopa in parkinson's disease.

Authors:  J R Bianchine; G M Shaw
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

Review 10.  Levodopa and decarboxylase inhibitors: a review of their clinical pharmacology and use in the treatment of parkinsonism.

Authors:  R M Pinder; R N Brogden; P R Sawyer; T M Speight; G S Avery
Journal:  Drugs       Date:  1976       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.